CTOs on the Move

Havas Health

www.havashealth.com

 
Havas Health houses Havas Life (formerly known as Euro RSCG Life), Health4brands (H4B), and Havas Lynx, three wholly-owned Health and Communications Networks, and defines policies and processes for the entire group. Its customer-centric approach has the talent, tenacity and technology that companies, brands and people need to thrive in today`s world.
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

TriStar StoneCrest Medical Center

StoneCrest Medical Center offers acute care services including emergency and intensive care, general surgery, cardiology, obstetrics, physical medicine, outpatient diagnostic services and cancer care. From the newest in cardiac ultrasound technology to the state-of-the-art catheterization lab, TriStar StoneCrest is equipped to deliver a range of services to help prevent, treat, and recover from heart disease and stroke. From screenings to diagnostic cardiac catheterization, from angioplasty to rehabilitation, TriStar StoneCrest`s services have earned a reputation for excellence.

The Avondale Care Group

The Avondale Care Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Optimal Radiology

Optimal Radiology is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mariner Health Care

Mariner Health Care is a San Pablo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.